Miles Prince Staff Profile
Prescient Therapeutics: Professor H. Miles Prince Professor H. Miles Prince AM, the Principal Investigator for...
Prescient Therapeutics: Professor H. Miles Prince Professor H. Miles Prince AM, the Principal Investigator for...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX) Reach Markets interviewed Co-Founder and Senior...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Prescient Therapeutics: Cell Therapies presentations from ISCT Prescient Therapeutics held a special Cell Therapies briefing...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.